A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. - Wikidata - wikimedia - TriplyDB

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

http://www.wikidata.org/entity/Q34093899

about

Neurodegeneration in multiple sclerosis: novel treatment strategies New and emerging disease modifying therapies for multiple sclerosis N-Acetylglucosamine Inhibits T-helper 1 (Th1)/T-helper 17 (Th17) Cell Responses and Treats Experimental Autoimmune Encephalomyelitis Current Concepts in Multiple Sclerosis: Autoimmunity Versus Oligodendrogliopathy Multiple Sclerosis: Where Will We Be in 2020?Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approach Treatment with disease modifying drugs for people with a first clinical attack suggestive of multiple sclerosis Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine The challenge of comorbidity in clinical trials for multiple sclerosis Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis Multiple sclerosis: the role of cytokines in pathogenesis and in therapies Diagnosis and Management of Multiple Sclerosis in Children No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis Clarity and strength of implications for practice in medical journal articles: an exploratory analysis Development of oral immunomodulatory agents in the management of multiple sclerosis Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS Cladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear Cells Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data Using historical control information for the design and analysis of clinical trials with overdispersed count data.A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis.Brain atrophy in multiple sclerosis: therapeutic, cognitive and clinical impact.Assessing changes in relapse rates in multiple sclerosis.Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs.Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis Cladribine tablets: in relapsing-remitting multiple sclerosis.3,3'-diindolylmethane ameliorates experimental autoimmune encephalomyelitis by promoting cell cycle arrest and apoptosis in activated T cells through microRNA signaling pathways.Clinical characteristics of multiple sclerosis in Kuwait: data from the new MS registry of Amiri Hospital.Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis : Analysis of Economic Data from the CLARITY Study.Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets Use of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ).Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.New approaches in the management of multiple sclerosis.Therapeutic strategies in childhood multiple sclerosis Chemotherapeutics in the treatment of multiple sclerosis.Chronic cladribine administration increases amyloid beta peptide generation and plaque burden in mice.

P2860

Q22241472-738F1BCC-CE45-4FD2-90A2-067148B3C2C8 Q22242305-963A0558-B9ED-414A-86E4-56A3BE959965 Q22248070-049A2ACD-7FD2-4F32-B4A6-BE4E0F22F144 Q22252578-219CDB7C-E752-493C-9D14-AF0A36858306 Q22252863-BE410CA5-76B8-4076-9161-0C609C8C9D8B Q22305854-EBAC1D3C-2A77-4B55-9475-51776DE7BB82 Q24185806-AB9BD6F8-3E4A-4C75-B51C-C3A3C756DD36 Q24185820-EEE29E0A-889A-450D-BDF9-E43C4B93F6B3 Q24597369-B6A8067F-84AD-4740-A58B-D9159A868403 Q26765031-79151D11-A08F-41B9-B08D-7A747FD9B93C Q26828463-1EE22047-F1D4-42C6-BE53-FC0D6FE73B19 Q27000269-37BFA153-2D0A-4065-8FB4-A2D4B0F8DB29 Q27011014-4AB8B18C-A872-40C9-B345-708CBEA44681 Q28069571-D662120F-6694-4EA0-9DC5-8F1EB2666D11 Q28268596-E48A3EA0-917B-46A1-89ED-3CE5821B7178 Q28281816-0DE817EC-9FAD-4B0D-BC60-DCCBEC0862F3 Q28387287-7EDDC1CD-AF1F-4AA0-8FBE-8DD21D96A639 Q28388704-8EF3EE58-A9FA-4A52-82E0-8EB20CE2B223 Q28478190-EAA464D8-101F-4126-9C92-921B6D3FD2A8 Q28548449-B2B3FC9A-C502-4E8F-BB9A-33F656CC853E Q30000824-3F0BE493-3D4A-4991-A66C-24519B73B6AC Q30636643-BB3D440D-3C5B-473C-BD01-457671F52E36 Q30716854-22147720-801F-42CC-8444-3237EA93ACF3 Q31070072-074D91C3-AE3B-416C-9076-80EDF422F177 Q33681680-18E0324F-9066-42E4-A01B-F7CBD377CF60 Q33777872-5BC5CA03-7746-47AB-BDA3-F7B63CF0F333 Q33802186-E67CD563-0CFD-4826-A720-25405BBC7DA4 Q33821160-1E19CFC8-1BF5-421A-A3B7-41A7DC2FED06 Q33944014-2F4F8F4D-EEC7-49A2-B35D-5A9998983419 Q34045441-36B98D24-C426-4495-9468-1AA034E05549 Q34053766-CCC4EA3E-141B-4771-99B9-CC0CDC0947E2 Q34100842-0EFBB6DE-4BCA-4642-B4E2-26F9E8DEF16A Q34133316-A2D6C6FE-B8E1-4946-9CB7-F642C77BC3CF Q34160752-E5320DEB-EB6F-43FD-A750-3E9BA65F3765 Q34184148-8721C735-E23D-4B77-ACD8-D4367DB94695 Q34257903-68A4AACA-5D85-4673-92E7-7540E8298E4A Q34389528-84E3B955-9E75-45BB-AF07-06947188B090 Q34409508-A4F2AE3F-8DAB-440E-B008-4C991C6E9763 Q34409536-2FE103D8-330A-40D3-B00E-ADDECEE0C6EE Q34441015-E546D19E-3C1A-4C52-AD5A-B503C45780CD

P2860

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

http://www.wikidata.org/entity/Q34093899

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

@ast

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

@en

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

@nl

type

label

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

@ast

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

@en

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

@nl

prefLabel

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

@ast

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

@en

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

@nl

P1433

Q34093899-37062C46-A740-42FC-A4C6-D84A1452AA89

P1476

Q34093899-2E935F11-66E4-4356-A444-432AA3F6EC76

P2093

Q34093899-047347DB-B70C-406C-B047-93B0160D57B9

Q34093899-22DC37B0-C3E3-410E-AC15-17CA737FFABA

Q34093899-2A8A4A79-F8E3-4AC8-9E23-344F4C4E8AD9

Q34093899-3197052E-7569-4A78-A8CE-5172CF4C552B

Q34093899-3A5F10AF-DFD9-4A7E-A46C-472F8B2DD96A

Q34093899-3ECD3154-F33E-4B2B-AA47-C7B702DD0C29

Q34093899-575AEE00-BF48-480A-B95F-0BBEDB76EA17

Q34093899-B4131D27-3987-4DB2-85B5-AFA49974C8F7

Q34093899-CD7FDC76-6006-4E59-9E9E-FB955A2B678A

P304

Q34093899-27928988-2DFE-420A-B644-48E8D42636B7

P31

Q34093899-433D1E67-8A2E-4569-8FB8-97BA806E687D

P356

Q34093899-05C4506F-8153-4768-9E74-03E50E0F09BF

P407

Q34093899-E687259E-BB9A-43F7-95BB-7BECD5BFCBF7

P433

Q34093899-FE379468-236F-4E58-8963-3923F966DBB4

P478

Q34093899-37EDABC3-17A7-4B3C-BA15-E6A949330C32

P50

Q34093899-4D53E19B-28A4-4A54-A570-A3BBBF827AB1

Q34093899-7E3F07DB-59AB-4DE4-8308-8294079C58CC

Q34093899-92E61CCD-38FF-475E-8E57-FA72F242A1B3

P577

Q34093899-07618108-348E-4083-9090-6DCE26BD1D08

P698

Q34093899-5AD4E8B4-3596-4EEE-8264-BC03B5A70FBC

P921

Q34093899-4F7CE4E1-C1DB-49EF-A886-38BE9398B9AD

Q34093899-A0650E3E-5AC5-4E33-9C4B-5F96EBC41EDA

P356

P1433

The New England Journal of Medicine

P1476

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

@en

P2093

Anthony Hamlett

http://www.w3.org/2001/XMLSchema#string

Bruno Musch

http://www.w3.org/2001/XMLSchema#string

CLARITY Study Group

http://www.w3.org/2001/XMLSchema#string

Kottil Rammohan

http://www.w3.org/2001/XMLSchema#string

Patrick Vermersch

http://www.w3.org/2001/XMLSchema#string

Peter Chang

http://www.w3.org/2001/XMLSchema#string

Peter Rieckmann

http://www.w3.org/2001/XMLSchema#string

Steven J Greenberg

http://www.w3.org/2001/XMLSchema#string

Stuart Cook

http://www.w3.org/2001/XMLSchema#string

P304

416-426

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0902533

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

362

http://www.w3.org/2001/XMLSchema#string

P50

Per Soelberg Sørensen

Gavin Giovannoni

P577

2010-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20089960

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis